WILMINGTON, Del., July 14, 2025 – Positive high-level results from the BaxHTN Phase III trial showed baxdrostat at two doses (2mg and 1mg) demonstrated a statistically significant and clinically meaningful reduction in mean seated systolic blood pressure (SBP) compared with placebo at 12 weeks. The trial also successfully met all secondary endpoints. Patients with uncontrolled or treatment resistant hypertension received baxdrostat or placebo on top of standard of care. Baxdrostat was generally well tolerated with a favorable safety profile.

There are 1.3 billion people worldwide living with hypertension.¹ When uncontrolled, hypertension can lead to a higher risk of heart attack, stroke, heart failure and kidney disease.^2,3 In the US, approximately 50% of hypertensive patients who are on multiple treatments do not have their blood pressure under control.⁴ Growing evidence points to aldosterone dysregulation as one of the key biological drivers of hypertension.^5,6